Brokers Set Expectations for Editas Medicine FY2026 Earnings

Editas Medicine, Inc. (NASDAQ:EDIT) – Equities researchers at Chardan Capital issued their FY2026 earnings estimates for shares of Editas Medicine in a research report issued on Thursday, November 13th. Chardan Capital analyst Y. Livshits forecasts that the company will earn ($1.41) per share for the year. Chardan Capital currently has a “Strong-Buy” rating on the stock. The consensus estimate for Editas Medicine’s current full-year earnings is ($2.71) per share.

Editas Medicine (NASDAQ:EDIT) last announced its quarterly earnings data on Monday, November 10th. The company reported ($0.28) EPS for the quarter, beating the consensus estimate of ($0.38) by $0.10. Editas Medicine had a negative net margin of 430.84% and a negative return on equity of 277.29%. The business had revenue of $7.54 million during the quarter, compared to the consensus estimate of $4.95 million.

Other equities analysts have also issued reports about the company. Wells Fargo & Company upped their target price on Editas Medicine from $3.00 to $4.00 and gave the stock an “equal weight” rating in a research report on Wednesday, September 3rd. Wall Street Zen raised Editas Medicine from a “sell” rating to a “hold” rating in a research report on Friday, September 26th. HC Wainwright reissued a “buy” rating and issued a $5.00 price target on shares of Editas Medicine in a report on Friday, September 5th. Robert W. Baird increased their price target on shares of Editas Medicine from $4.00 to $6.00 and gave the company an “outperform” rating in a research report on Wednesday, August 13th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Editas Medicine in a research report on Wednesday, October 8th. Two analysts have rated the stock with a Strong Buy rating, three have given a Buy rating, five have issued a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat.com, Editas Medicine presently has an average rating of “Hold” and an average target price of $3.88.

Editas Medicine Stock Performance

EDIT stock opened at $2.60 on Monday. The company has a market capitalization of $253.81 million, a P/E ratio of -1.09 and a beta of 2.23. The company has a fifty day moving average price of $3.23 and a 200-day moving average price of $2.63. Editas Medicine has a 52-week low of $0.91 and a 52-week high of $4.54.

Hedge Funds Weigh In On Editas Medicine

Several institutional investors have recently modified their holdings of the company. Victory Capital Management Inc. purchased a new position in Editas Medicine in the 3rd quarter worth approximately $36,000. Captrust Financial Advisors purchased a new stake in Editas Medicine during the 2nd quarter valued at $26,000. Sei Investments Co. bought a new stake in shares of Editas Medicine during the 3rd quarter valued at about $46,000. Baader Bank Aktiengesellschaft purchased a new position in shares of Editas Medicine during the 3rd quarter worth $50,000. Finally, SG Americas Securities LLC purchased a new position in shares of Editas Medicine during the 3rd quarter valued at about $51,000. 71.90% of the stock is currently owned by institutional investors.

Editas Medicine Company Profile

Editas Medicine, Inc, a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia.